Physician profile
Erno Berdy
NPI 1851376941
$1,735.08
in general payments reported to CMS, 2019-2025
29 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $55.49 · 2021: $134 · 2022: $273 · 2023: $139 · 2024: $315 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $233.45 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $160.93 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $116.90 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $73.92 | 2020-2025 | Airsupra, Breztri |
| Ferring Pharmaceuticals INC. | $69.64 | 2025 | Rebyota |
| Astellas Pharma US INC | $58.25 | 2019-2021 | |
| Amarin Pharma, INC. | $42.65 | 2019 | |
| Pfizer INC. | $41.20 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.59 | 2025 | Caplyta |
| Ethicon INC. | $31.37 | 2025 | Monarch Platform |
| Abbott Laboratories | $30.73 | 2019-2022 | |
| Edwards Lifesciences Corporation | $29.97 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.11 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $21.09 | 2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $20.66 | 2022 | |
| Abbvie INC. | $19.44 | 2019 | |
| Abiomed | $18.89 | 2023 | Impella |
| Glaxosmithkline, LLC. | $17.81 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.36 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2022 | |
| Valeritas, INC. | $13.83 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.90 | 2023 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $12.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.41 | 2019 | |
| Seqirus USA INC | $11.94 | 2022 | |
| Merck Sharp & Dohme LLC | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erno Berdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.